Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty.

Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty. - Alendronate for the Prevention of Bone Loss around Total Hip Arthroplasty.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027501

Enrollment

Registered

2017-05-26

Start date

2006-08-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of hip joint

Interventions

Administration of alendronate(5mg/day) after total hip arthroplasty atleast 2 years. Administration of alphacalcidolfollowing(0.001g/day) total hip arthroplasty atleast 2 years. No medication after

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent primary total hip arthroplasty for osteoarthritis at our institute

Exclusion criteria

Exclusion criteria: (a) a history of disorder(s) that might affect bone or mineral metabolism, (b) gastrointestinal disease, (c) renal dysfunction, (d) taking any agents for osteoporosis, (e) taking corticosteroids, and (f) perioperative fracture of femur that required additional fixation using plates and wires.

Design outcomes

Primary

Measure	Time frame
Periprosthetic bone mineral density measured by dual-energy X-ray(Postoperative 1-year, 2-year, 8 to 9-year)	—

Secondary

Measure	Time frame
Occurrence of aseptic loosening and periprsthetic fracture	—

Countries

Japan

Contacts

Public ContactInaba, Yutaka

Yokohama City University Orthopaedic Surgery

yute0131@med.yokohama-cu.ac.jp045-787-2600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026